Theravance Biopharma (TBPH) Set to Announce Quarterly Earnings on Monday

Theravance Biopharma (NASDAQ:TBPH) will be releasing its earnings data after the market closes on Monday, August 5th. Analysts expect the company to announce earnings of ($0.09) per share for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings data on Monday, May 13th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.04. Theravance Biopharma had a negative net margin of 72.79% and a negative return on equity of 18.97%. The business had revenue of $14.50 million during the quarter, compared to the consensus estimate of $14.54 million. On average, analysts expect Theravance Biopharma to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Theravance Biopharma Price Performance

NASDAQ TBPH opened at $9.64 on Friday. The company has a market cap of $468.79 million, a price-to-earnings ratio of -11.21 and a beta of 0.24. The stock’s fifty day moving average price is $9.04 and its 200 day moving average price is $9.10. Theravance Biopharma has a 1 year low of $8.13 and a 1 year high of $11.71.

Insider Transactions at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the transaction, the senior vice president now directly owns 335,965 shares in the company, valued at $3,023,685. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 6.90% of the company’s stock.

Wall Street Analysts Forecast Growth

TBPH has been the subject of several research analyst reports. BTIG Research assumed coverage on Theravance Biopharma in a research note on Friday, April 12th. They issued a “buy” rating and a $21.00 price objective for the company. HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Theravance Biopharma in a research report on Wednesday, May 29th. Finally, StockNews.com downgraded shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Thursday.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.